Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ShotBlocker During Intramuscular Injection Randomized Control Trial

NCT: NCT06624176 · RECRUITING

NCT IDNCT06624176
StatusRECRUITING
Start Date2024-01-10
Completion2026-10-01
SponsorLauren Fortier (OTHER)
First posted
Last updated

Brief Summary

The objective of this trial is to evaluate the effect of Bionix ShotBlocker on pain of injection of the first Hepatitis B vaccine in healthy newborns. ShotBlocker is a pain reducing tool used in babies, children, and adults for injections. Swaddling during the injection and administration of oral sucrose prior to the injection are established standards of care for painful procedures in neonates. The investigators hypothesize that the use of ShotBlocker in addition to swaddling and oral sucrose administration will lessen the pain response.

Frequently Asked Questions

What is ShotBlocker During Intramuscular Injection Randomized Control Trial?

ShotBlocker During Intramuscular Injection Randomized Control Trial is a clinical trial registered under NCT06624176. Current status: RECRUITING.

What is the status of NCT06624176?

The current status of NCT06624176 (ShotBlocker During Intramuscular Injection Randomized Control Trial) is: RECRUITING.

When did ShotBlocker During Intramuscular Injection Randomized Control Trial start?

ShotBlocker During Intramuscular Injection Randomized Control Trial started on 2024-01-10.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.